Becton, Dickinson and Company (LON:0R19)

London flag London · Delayed Price · Currency is GBP · Price in USD
194.41
+1.63 (0.85%)
At close: Aug 13, 2025
-17.42%
Market Cap 41.39B
Revenue (ttm) 15.61B
Net Income (ttm) 1.16B
Shares Out n/a
EPS (ttm) 3.99
PE Ratio 35.78
Forward PE 13.59
Dividend 3.11 (1.59%)
Ex-Dividend Date Jun 9, 2025
Volume 810
Average Volume 1,736
Open 195.21
Previous Close 192.78
Day's Range 193.94 - 196.12
52-Week Range 163.64 - 251.08
Beta 0.22
RSI 67.86
Earnings Date Aug 7, 2025

About LON:0R19

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 1897
Employees 74,000
Stock Exchange London Stock Exchange
Ticker Symbol 0R19
Full Company Profile

Financial Performance

In 2024, LON:0R19's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.

Financial numbers in USD Financial Statements

News

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J. , July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination produ...

22 days ago - PRNewsWire

BD Board Declares Dividend

FRANKLIN LAKES, N.J. , July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla...

22 days ago - PRNewsWire

Best Dividend Kings: July 2025

14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...

22 days ago - Seeking Alpha

Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio ? Elevance Health, Inc. (NYSE: ELV) shares decreased 17.96% this week after the company lowered its f...

24 days ago - Benzinga

WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger o...

4 weeks ago - Business Wire

How Do Investors Really Feel About Becton Dickinson?

Becton Dickinson's (NYSE: BDX) short percent of float has risen 21.62% since its last report. The company recently reported that it has 3.90 million shares sold short , which is 1.35% of all regular ...

4 weeks ago - Benzinga

Waters to buy Becton Dickinson unit in a $17.5 billion deal amid tariff pressures

Waters Corp will buy a unit spun off from medtech provider Becton Dickinson in a stock-and-cash transaction valued at $17.5 billion, the companies said.

4 weeks ago - CNBC

Analytics Equipment Maker Waters Buys Becton Dickinson Unit in a $17.5B Deal

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 billion.

4 weeks ago - Investopedia

Becton Dickinson gets its spinoff deal, but the stock is still falling

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.

4 weeks ago - MarketWatch

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to ...

4 weeks ago - PRNewsWire

BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

FRANKLIN LAKES, N.J. , July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin ha...

5 weeks ago - PRNewsWire

Best Dividend Aristocrats For July 2025

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising pa...

6 weeks ago - Seeking Alpha

New vaccine panel meeting underway

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.

6 weeks ago - CNBC Television

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

Shares of Becton Dickinson and Company (NYSE: BDX) are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasti...

7 weeks ago - Benzinga

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until ...

7 weeks ago - Benzinga

Best Dividend Kings: June 2025

Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and a c...

7 weeks ago - Seeking Alpha

New Jersey Rep. Thomas Kean Bought Over $4K Worth of Amazon.com Stock: Here's What You Should Know

An official report on June 17, 2025 reveals Representative Thomas Kean's recent purchase of Amazon.com (NASDAQ: AMZN) stock, valued between $4,004 and $60,000. The transaction took place on May 8, 20...

2 months ago - Benzinga

June's Top Dividend Aristocrat Fat Pitches: Blue-Chip Bargains You Can't Miss

Despite bubble fears, 91% of market gains since 2009 are justified by fundamentals like earnings, dividends, and strong balance sheets. Stocks appear overvalued at face value, but strong long-term ear...

2 months ago - Seeking Alpha